SIX Swiss Exchange · Healthcare
Invest in Basilea Pharmaceutica stock from India
Indian and foreign residents can buy Basilea Pharmaceutica (BSLN) shares directly through Paasa.
By Paasa · Updated
Basilea Pharmaceutica at a glance
- Price
- CHF 68.70-CHF 0.40 (0.58%)
- Market cap
- CHF 850.28M
- Day range
- CHF 68.30 – CHF 69.40
- P/E
- 16.13
- Dividend yield
- None
- Volume
- 17.46K
- 1 month
- +4.89%
- 6 months
- +30.86%
- YTD
- +26.06%
- 1 year
- +51.99%
- 5 years
- +49.93%
Basilea Pharmaceutica statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CHF 232.4M | CHF 208.5M | CHF 157.6M | CHF 147.8M | CHF 148.1M |
| Gross profit | CHF 193.1M | CHF 169.9M | CHF 130.8M | CHF 121.0M | CHF 124.0M |
| Operating income | CHF 51.6M | CHF 61.2M | CHF 19.2M | CHF 18.5M | CHF 1.2M |
| Net income | CHF 40.2M | CHF 77.6M | CHF 10.5M | CHF 12.1M | −CHF 6.8M |
| Earnings per share | CHF 3.29 | CHF 6.42 | CHF 0.87 | CHF 1.02 | −CHF 0.58 |
| EBITDA | CHF 55.3M | CHF 63.1M | CHF 23.2M | CHF 26.2M | CHF 6.7M |
| Total assets | CHF 282.0M | CHF 257.8M | CHF 173.3M | CHF 220.8M | CHF 247.3M |
| Total debt | CHF 89.2M | CHF 111.7M | CHF 128.6M | CHF 187.1M | CHF 219.0M |
| Cash and short-term investments | CHF 162.3M | CHF 120.7M | CHF 59.9M | CHF 84.7M | CHF 148.7M |
| Shareholders' equity | CHF 127.9M | CHF 81.0M | −CHF 10.0M | −CHF 20.7M | −CHF 58.6M |
| Operating cash flow | CHF 62.1M | CHF 74.4M | CHF 14.2M | CHF 7.1M | −CHF 32.0M |
| Free cash flow | CHF 59.2M | CHF 72.7M | CHF 13.2M | CHF 3.8M | −CHF 32.9M |
| Capital expenditure | −CHF 2.9M | −CHF 1.7M | −CHF 1.0M | −CHF 3.3M | −CHF 860.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CHF; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| PolyPeptide | PPGN.SW | CHF 44.10 | CHF 1.46B |
| Idorsia | IDIA.SW | CHF 4.44 | CHF 1.17B |
| DocMorris | DOCM.SW | CHF 11.44 | CHF 559.29M |
| IVF Hartmann | VBSN.SW | CHF 129.00 | CHF 307.20M |
| Santhera Pharmaceuticals | SANN.SW | CHF 15.22 | CHF 225.73M |
| Newron Pharmaceuticals | NWRN.SW | CHF 10.46 | CHF 217.63M |
| Molecular Partners | MOLN.SW | CHF 3.22 | CHF 120.79M |
| Relief Therapeutics | RLF.SW | CHF 2.89 | CHF 36.28M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Basilea Pharmaceutica from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.
Step 3
Search BSLN and buy
Find Basilea Pharmaceutica by name or by its ticker, BSLN, and place your order.
Why invest in Basilea Pharmaceutica from India
What Basilea Pharmaceutica does
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. Basilea Pharmaceutica operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Basilea Pharmaceutica stock from India?
Yes. Indian residents and NRIs can buy Basilea Pharmaceutica (BSLN) shares directly through Paasa. Basilea Pharmaceutica is listed on the SIX Swiss Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Basilea Pharmaceutica shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.